Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Divestments (2021 - 2025)

Historic Divestments for BridgeBio Pharma (BBIO) over the last 3 years, with Q3 2025 value amounting to $2.3 million.

  • BridgeBio Pharma's Divestments changed N/A to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 9103.65%. This contributed to the annual value of $25.7 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that BridgeBio Pharma reported Divestments of $2.3 million as of Q3 2025.
  • BridgeBio Pharma's Divestments' 5-year high stood at $29.4 million during Q4 2021, with a 5-year trough of $2.3 million in Q3 2025.
  • Its 3-year average for Divestments is $19.1 million, with a median of $25.7 million in 2024.